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Bhe birth of modern science was ushered in by the great
ntellectual revolution that occurred during the Renaissance,
hen irreverent thinkers began to question centuries-old
ogmas imposed on the populace by an establishment of
avants intent on maintaining their supremacy. The procliv-
ty of erudite oligarchies to enforce dogmas, however, did
ot vanish after the Renaissance, as documented by many
nstances in which innovative scientists were subjected to
reat hardship for daring to challenge existing paradigms.
ndeed, the history of science, far from being a smooth
volutionary process, has been punctuated by a series of
evolutions, big and small. It seems likely that the everlast-
ng conflict between the attempts of intellectual elites to
aintain their power through the promulgation of axioms
nd the insuppressible drive of the free mind to verify the
eracity of ideas will continue as long as human nature
emains what it is.
See page 1651
A veritable revolution is now unfolding in the field of
ardiac biology, where a fundamental tenet that has been
enerated for several decades, namely, that the heart is a
ostmitotic organ incapable of regeneration, has come
nder attack of late. According to this dogma, the number
f cardiac myocytes we are born with is all we will have for
he rest of our lives; if myocytes die (e.g., as the result of
nfarction), they cannot be replaced. This rather bleak
octrine has been challenged for 20 years by the observa-
ions of Anversa et al. (1–3), which have laid the foundation
nd provided the ammunition for the present revolution in
ardiac regeneration. The spark that ignited the fire came in
001, at the dawn of the new millennium, when Orlic et al.
4) demonstrated that bone marrow (BM) cells can recon-
titute infarcted myocardium in mice. Since then, research
as moved at lightning speed. A year later, Strauer et al. (5)
eported that BM cell transplantation improves cardiac
unction in patients with acute myocardial infarction (MI)
nd within months a deluge of clinical studies (6–11),
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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L-78825.ncluding a randomized clinical trial (12), suggested that
M cell therapy exerts beneficial effects in various subsets of
atients with ischemic heart disease (13). The flood gates
ad opened. The rapidity with which the basic observations
f Orlic et al. (4) have been translated into clinical studies is
nprecedented. Almost overnight, the approach to acute MI
nd heart failure has changed, and the focus has shifted on
rying to achieve what was previously unthinkable (accord-
ng to the dogma): To reconstitute dead myocardium.
In this issue of the Journal, Strauer et al. (14) broaden the
evolution by describing the results of intracoronary admin-
stration of autologous BM mononuclear cells in 18 patients
ith chronic transmural MI. They found an improvement
n regional and global left ventricular function and in
xercise capacity, associated with an increase in perfusion
nd glucose uptake in the infarcted region. The first trial of
M cells in chronic ischemic cardiomyopathy was per-
ormed by Perin et al. (7). That study used percutaneous
ransendocardial injection of BM cells and provided encour-
ging results, as did other investigations (8,9). The impor-
ance of the present study (14) lies in the fact that it used the
ntracoronary route to perform cellular cardiomyoplasty in
atients with chronic ischemic heart disease. Strauer et al.
14) did not observe any complications, such as arrhythmias,
estenosis, distal embolism with microinfarction, changes in
arkers of inflammation, or depressed myocardial function,
uggesting that the delivery of BM cells by the intracoronary
oute is safe. Although these observations are limited by the
hort follow-up (three months) and the small sample
xamined (18 patients), they are consonant with those
btained in acute MI, in which the experience accumulated
ith 170 patients enrolled in various trials worldwide
5,6,10–12,15) supports the safety of intracoronary BM and
rogenitor cell injection (13). Therefore, in response to
hose who regard human studies of BM cells for myocardial
epair as premature because the mouse data are not consis-
ent (16), one could argue that, given the evidence for safety
nd feasibility and the preliminary evidence for efficacy (13),
t would be unethical to withhold such studies, which have
he potential to offer a revolutionary treatment for heart
isease, simply because some investigators have reported
egative results in the mouse. Even in the mouse, the
reponderance of the evidence supports the feasibility of
M cell-mediated cardiac regeneration (13). Besides, as a
rilliant thinker once put it, “mice are not people.”
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Editorial Comment November 1, 2005:1659–61Despite the novelty and potential impact of the observa-
ions of Strauer et al. (14), a number of limitations must be
ecognized. First and foremost, their investigation was not
andomized. Because of this, and because of its small size
nd short-term follow-up, this study is far from providing
onclusive evidence for efficacy. It is also unclear whether
he analyses of cardiac function and metabolism were
linded. Because patients were not blinded, the results of
xercise spiroergometry could have been biased in favor of
reatment. Additional assessment of ventricular function by
chocardiography or magnetic resonance imaging would
ave strengthened the conclusions. It would be important to
now the exact frequency distribution of various cell types
CD45/CD14, AC133, CD34) in the mononuclear
M cell preparation that was injected. Finally, it would have
een useful to specify the extent of the initial metabolic and
erfusion defects (assessed by fluorodeoxy glucose and
etrofosmin uptake, respectively) in the control and treated
roups; this would have clarified whether the two groups
ere comparable before treatment.
The mechanism for the salubrious effects of BM cells
bserved by Strauer et al. (14) remains a matter of specu-
ation. The comparatively greater increase in fluorodeoxy
lucose uptake vis-a-vis the increase in perfusion (assessed
s tetrofosmin uptake) strongly supports regeneration of
yocytes as the basis for the improvement in function. Of
he four possibilities put forth by the authors (14) (i.e.,
ransdifferentiation of BM cells into cardiac myocytes,
ctivation of resident cardiac stem cells by BM-derived
ytokines, proliferation of residual viable myocytes induced
y BM-derived cytokines, and fusion between BM cells and
urviving myocytes), the first two appear to be the most
lausible. Cardiac stem cells, characterized by Beltrami et al.
17) both in vitro and in vivo and also described by others
18–20), can effect cardiac repair and improvement in
unction when delivered by the intramyocardial (17) or the
ntracoronary (21) route and could be activated by BM cells
ia paracrine mechanisms (e.g., release of growth factors).
n the other hand, it is implausible that the fusion between
BM cell and a preexisting myocyte will result in improved
unction; there is no evidence or theoretical reason to
upport this conjecture. An additional mechanism to be
onsidered is based on the recent work by Kucia et al. (22),
ho have found in the BM a pool of CXCR4/lin/
D45, nonhematopoietic stem cells that express early
ardiac lineage markers (Nkx2.5/Csx, GATA-4, and
EF2C) and therefore appear to be committed to differ-
ntiation into the cardiac lineage. Kucia et al. (22) proposed
hat these cardiac progenitors contribute to BM-dependent
ardiac regeneration by differentiating into cardiac myocytes
nd vascular cells, a paradigm that involves neither cell
usion nor transdifferentiation of hematopoietic stem cells.
Asides from their obvious therapeutic implications, the
ew ideas that are emerging from the current stem cell
evolution may explain why the BM is the most protected
rgan in the body, even more than the brain. It is locatedeep inside our bones, and as if this were not enough, it is
pread in multiple locations so that loss of one bone will not
ause loss of function. Why is nature so compulsive in
rotecting the marrow? Why does hematopoiesis have to be
erformed inside the bone rather than in the liver or spleen,
here it occurs during fetal development? Nature always
oes things for a good reason. The studies reviewed in this
rticle (5–12,14) support the concept that the BM is a
eservoir of stem cells that have the potential to differentiate
nto cardiac lineage and that may be continually released
nto the peripheral blood to reach the heart where they
ontribute to its physiological turnover. Similarly, the BM
ay be responsible for the turnover of other tissues as well.
n this scenario, the BM would be truly our most important
rgan, the one that needs to be protected most jealously.
In summary, Strauer et al. (14) have made an important
ontribution to the field of myocardial regeneration by
roviding evidence that intracoronary administration of BM
ells improves cardiac function in patients with chronic
schemic cardiomyopathy. These observations, although
ntriguing, are still preliminary and need to be validated in
uture studies. The results of Stauer et al. (14) provide a
ationale for more definitive clinical trials, which should
ave the following features: 1) they should be randomized,
ouble-blind, controlled, and adequately powered; 2) a long
ollow-up period should be used to document persistent
eneficial effects and possible chronic untoward effects (such
s neoplasms); and 3) cardiac function should be assessed
ith state-of-the-art imaging modalities, such as magnetic
esonance imaging, in conjunction with assessment of myo-
ardial metabolism and perfusion with positron emission
omography. Despite these notes of caution, however, let us
ot lose sight of the enormous progress that has been made
n just four years since the report by Orlic et al. (4). These
re truly momentous times. Old dogmas are crumbling
hile new ideas are spreading like wildfire. The outcome is
ncertain, but we can be assured that in the end the truth
ill prevail, as it always does in science. If cardiac regener-
tion is indeed possible, the stem cell revolution will prove
o be one of the most significant, if not the most significant,
onceptual and therapeutic advances in cardiovascular med-
cine.
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f Cardiology, 550 South Jackson Street, 3rd Floor, Ambulatory Care
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